Alkermes plc VP Samuel Joseph Parisi sells $47,360 in stock

Samuel Joseph Parisi, the Vice President of Finance and Interim Principal Accounting Officer at Alkermes plc (NASDAQ:ALKS), a pharmaceutical company with a market capitalization of $5.77 billion and an "GREAT" financial health score according to InvestingPro, recently executed a series of stock transactions, according to a Form 4 filing with the U.S. Securities and Exchange Commission. On February 20, Parisi sold 1,327 ordinary shares at a price of $35.69 per share, totaling approximately $47,360. This sale was conducted under a Rule 10b5-1 trading plan he adopted in September 2024.

Additionally, Parisi disposed of 706 shares on February 18 at $35.90 each, amounting to a total of $25,345. Prior to these transactions, Parisi acquired 2,033 ordinary shares through the exercise of restricted stock units, although these acquisitions did not involve any cash exchange.

Following these transactions, Parisi holds 7,717 shares directly. The transactions reflect Parisi’s ongoing management of his holdings in the company, which is headquartered in Dublin and operates in the pharmaceutical preparations sector.

In other recent news, Alkermes reported strong financial results for the fourth quarter of 2024, with earnings per share (EPS) of $1.05 and revenues of $430 million, both exceeding expectations. The company provided guidance for 2025, projecting total revenues between $1.34 billion and $1.43 billion and an EBITDA range of $215 million to $245 million. Analysts from Goldman Sachs, Cantor Fitzgerald, and Jefferies provided positive outlooks on Alkermes, with Goldman Sachs raising the price target to $32, Cantor Fitzgerald maintaining a $43 target, and Jefferies setting a $41 target. Goldman Sachs noted Alkermes’ performance in the fourth quarter of 2024 surpassed expectations, and Cantor Fitzgerald emphasized the company’s potential pipeline expansion. Jefferies highlighted the company’s strong quarterly performance and favorable guidance for the upcoming years. Alkermes’ commitment to advancing its pipeline, particularly in the Orexin agonist space, is attracting investor attention, with key data releases anticipated in the coming years. The company’s strategic initiatives and upcoming milestones are expected to benefit patient investors, as noted by analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.